Retrospective Study of Metastatic Left Colon and Rectal Cancer as Regard Treatment With Anti_EGFR Targeted Therapy
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Metastatic Colorectal Adenocarcinoma
- Sponsor
- Assiut University
- Enrollment
- 100
- Primary Endpoint
- OS and DFS of patients with metastatic colorectal cancer patients received anti_EGFR targeted therapy
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
Colorectal cancer ranks the second lethal cancer and third prevalent malignant tumour worldwide, Despite of different odern modalities for diagnosis,large number of cases diagnosed at metastatic advanced stage .
New treatment approach has been discovered habe been discovered making a huge revolution in metastatic colorectal cancer represented by targeted therapy including anti_EGFR ,anti_angiogenic and kinase inhibitors .
Detailed Description
Retrospective study aims to evaluate the effect of EGFR expression in metastatic colorectal cancer and the outcome of treatment with anti_EGFR targeted therapy between left colon and rectal cancer
Investigators
Esraa Ebrahim mohammed
Principal investigator1
Assiut University
Eligibility Criteria
Inclusion Criteria
- •age above 18
- •Performance status zero to one according to ECOG scale system
- •Histo-pathologial diagnosis adenocarcinoma of left colon or rectum.
- •Patients diagnosed with left colon and rectal cancer.
- •Patients eligible to receive chemotherapy (with renal and liver chemistry, and normal CBC.
- •Patients diagnosed with metastatic stage.
- •K-RAS wild type.
Exclusion Criteria
- •Second malignancy
- •Histo-pathological types other than adenocarcinoma.
- •Right colon cancer patients.
- •Patients refused receiving anti_EGFR targeted therapy.
- •Patients with any abnormalities preventing to receive chemotherapy.
- •Early stages of colorectal cancer.
- •K-RAS mutant type.
Outcomes
Primary Outcomes
OS and DFS of patients with metastatic colorectal cancer patients received anti_EGFR targeted therapy
Time Frame: Anti_EGFR targeted therapy in assuit university hospitals from 2015 to 2022
Evaluation of anti-EGFR targeted therapy on metastatic cancer rectum and left colon and factors affecting response to treatment
Secondary Outcomes
- Response rate (RR) in patients received chemotherapy only or with combination with targeted therapy.(The response of patients to EGFR targeted therapy in AUH at period from 2015 to 2022)